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Abstract: The widespread use of highly active antiretroviral treatments has dramatically changed the
prognosis of people living with HIV (PLWH). However, such treatments have to be taken lifelong raising
issues regarding the maintenance of both therapeutic effectiveness and long-term tolerability. Recently
approved or investigational antiretroviral drugs present considerable advantages, allowing once daily oral
dosage along with activity against resistant variants (eg, bictegravir and doravirine) and also parenteral
intramuscular administration that facilitates treatment adherence (eg, long-acting injectable formulations
such as cabotegravir and rilpivirine). Still, there remains a risk of insufficient or exaggerated circulating
exposure due to absorption issues, abnormal elimination, drug-drug interactions, and others. In this
context, a multiplex ultra-high performance liquid chromatography coupled to tandem mass spectrom-
etry (UHPLC-MS/MS) bioassay has been developed for the monitoring of plasma levels of bictegravir,
cabotegravir, doravirine, and rilpivirine in PLWH. A simple and convenient protein precipitation was
performed followed by direct injection of the supernatant into the UHPLC-MS/MS system. The four
analytes were eluted in less than 3 minutes using a reversed-phase chromatography method coupled with
triple quadrupole mass spectrometry detection. This bioassay was fully validated following international
guidelines and achieved good performances in terms of trueness (94.7%-107.5%), repeatability (2.6%-
11%), and intermediate precision (3.0%-11.2%) over the clinically relevant concentration ranges (from 30
to 9000 ng/mL for bictegravir, cabotegravir, and doravirine and from 10 to 1800 ng/mL for rilpivirine).
This sensitive, accurate, and rapid UHPLC-MS/MS assay is currently applied in our laboratory for rou-
tine therapeutic drug monitoring of the oral drugs bictegravir and doravirine and is also intended to be
applied for the monitoring of cabotegravir/rilpivirine levels in plasma from PLWH receiving once monthly
or every 2-month intramuscular injection of these long-acting antiretroviral drugs.
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The widespread use of highly active antiretroviral treatments has dramatically changed
the prognosis of people living with HIV (PLWH). However, such treatments have to be
taken lifelong raising issues regarding the maintenance of both therapeutic effective-
nessand long-termtolerability.Recently approvedor investigational antiretroviral drugs
present considerable advantages, allowing once daily oral dosage along with activity
against resistant variants (eg, bictegravir anddoravirine) and alsoparenteral intramuscu-
lar administration that facilitates treatment adherence (eg, long-acting injectable formu-
lations such as cabotegravir and rilpivirine). Still, there remains a risk of insufficient or
exaggerated circulating exposure due to absorption issues, abnormal elimination, drug-
drug interactions, and others. In this context, a multiplex ultra-high performance liquid
chromatography coupled to tandemmass spectrometry (UHPLC-MS/MS) bioassay has
been developed for the monitoring of plasma levels of bictegravir, cabotegravir, dora-
virine, and rilpivirine in PLWH. A simple and convenient protein precipitation was per-
formed followedby direct injection of the supernatant into theUHPLC-MS/MS system.
The four analyteswere eluted in less than 3minutes using a reversed-phase chromatog-
raphymethod coupled with triple quadrupolemass spectrometry detection. This bioas-
say was fully validated following international guidelines and achieved good
performances in termsof trueness (94.7%-107.5%), repeatability (2.6%-11%), and inter-
mediate precision (3.0%-11.2%) over the clinically relevant concentration ranges (from
30 to 9000 ng/mL for bictegravir, cabotegravir, and doravirine and from 10 to 1800
ng/mL for rilpivirine). This sensitive, accurate, and rapid UHPLC-MS/MS assay is cur-
rently applied in our laboratory for routine therapeutic drugmonitoring of the oral drugs
bictegravir and doravirine and is also intended to be applied for the monitoring of
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cabotegravir/rilpivirine levels in plasma from PLWH receiving once monthly or every
2-month intramuscular injectionof these long-acting antiretroviral drugs.
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1 | INTRODUCTION
Optimal efficacy and good tolerability are key points during the
development of antiretroviral (ARV) drugs.1 Yet, besides therapeutic
effectiveness and drug safety profile, long-term adherence is required
to achieve viral suppression.2,3 The development of long-acting inject-
able (LAI) formulations can overcome the adherence issue4 by
maintaining effective plasma concentrations over months. Thus, LAI
has the potential to improve adherence thereby preventing drug resis-
tance. In addition, LAI can improve patients' privacy and reduce social
stigmas associated with daily intake of ARV drugs. It has been stated
that about as much as 50% to 70% of people living with HIV (PLWH)
would be interested in LAI formulations when available.5
Cabotegravir and rilpivirine are the first two drugs of LAI formula-
tion, currently in final phase of clinical development.6,7Cabotegravir is a
potentHIV integrase strand transfer inhibitor (INSTI),8while rilpivirine is
non-nucleoside HIV reverse transcriptase inhibitor (NNRTI). Long
plasma half-life of both substances made them good candidates for the
development of LAI formulations administered monthly9,10 or every
2months.11 Inaddition toHIV treatment, LAI-ARVdrugsarealso investi-
gated separately in the indication of pre-exposure prophylaxis (PreP).
Whether used for treatment or prevention, important pharmacokinetic
variability was shown following intramuscular injection of cabotegravir
and rilpivirine in clinical trials.9,10,12-14 These clinical studies have gener-
ally included carefully selected PLWH,whomay not reflect the complex
situation in a real-life clinical setting. In particular, drug-drug interactions
(DDIs) are likely tooccur,15 alsowith LAI-ARVdrugs, andwehave at pre-
sent very limited informationon their actual clinical importance, prompt-
ing themonitoring ofARVplasma levelswhennewcomedications at risk
of DDIs are introduced in patients on LAI-ARV drugs. Besides, inter-
subject variabilitymay bemore pronounced particularly in special popu-
lation (ie, underweight or obese patients, hepatic or renal impairment,
aging, or pregnancy).
In addition to these novel injectable formulations, ARV develop-
ments are also focused on improving the safety and tolerability pro-
file. The last-generation ARV drugs bictegravir (a potent unboosted
INSTI16) and doravirine (a next-generation NNRTI17) represent attrac-
tive oral therapeutic options because of their improved tolerability
profiles. Both bictegravir and doravirine are substrates of CYP3A4
and can consequently be victims of DDIs. However, there is currently
a lack of data concerning the magnitude of DDIs with these novel
ARV drugs. Yet, in the next few years, most PLWH in middle- and
high-income countries will switch to one of these last-generation ARV
therapies, either oral or LAI formulations.
The availability of liquid chromatography coupled to tandem mass
spectrometry (LC-MS/MS) methodologies for the determination of
ARV concentrations in human plasma is a key aspect for drug pharma-
cokinetic studies and therapeutic drug monitoring (TDM) in patients.
Several assays have been previously developed for the measurement
of rilpivirine as oral formulation.18-20 To the best of our knowledge,
only two LC-MS/MS assays have been published for the quantifica-
tion of bictegravir in human plasma.21,22 In addition, although cab-
otegravir and doravirine plasma concentrations have been determined
in several studies,23,24 no publication has been dedicated to the devel-
opment and the validation of such LC-MS/MS methodologies.
In this article, we aimed at developing and validating a simple and
fast multiplex assay by ultrahigh-performance liquid chromatography
coupled to tandem mass spectrometry (UHPLC-MS/MS) for the simul-
taneous determination of the latest generation ARV drugs bictegravir,
cabotegravir, doravirine, and rilpivirine in human plasma.
2 | MATERIAL AND METHODS
2.1 | Chemical and reagents
Bictegravir (purity ≥98%) and cabotegravir (≥98%) were obtained from
Alsachim (Strasbourg, France), while doravirine (98%) and rilpivirine
(98.5%) were purchased from Toronto Research Chemical (Toronto,
Canada). Chemical structures are depicted in Figure 1. Their stable
isotopically labelled internal standards (ISs) (ie, [13C,
2H2,
15N]-
bictegravir [purity ≥98%], [13C,
2H5]-cabotegravir [≥95%], [
13C6]-
doravirine [≥95%], and [13C6]-rilpivirine [99.3%]), were obtained from
Alsachim. In addition, cabotegravir O-β-D-glucuronide (purity 95%)
was purchased from Alsachim.
All solvents (ie, acetonitrile [ACN], methanol [MeOH], and formic
acid [FA] [98%-100%]) were of analytical grade and were obtained
from Merck (Darmstadt, Germany). Dimethylsulfoxide (DMSO, 99.5%)
was purchased from Alfa Aesar (Kandel, Germany). Ultrapure water
was supplied by a Milli-Q UF-Plus apparatus (Millipore Corp, Burling-
ton, MA, USA).
Human blank plasma samples used for method development and
validation, as well as for the preparation of calibration samples and
quality controls (QCs), were obtained according to institutional ethical
standard from citrated blood from patients with polycythemia vera
who underwent regular phlebotomy at the Center of Transfusion
Medicine, Lausanne University Hospital, Lausanne, Switzerland, by
centrifugation (1970g, ie, 3000 rpm, 10 min, +4C, Hettich model
Rotanta 460RF centrifuge) or from TCS Bioscience (Buckingham, UK).




2.2 | Stock solutions preparation
Each analyte was weighed and dissolved in the required volume of
solvent. Stock solutions of bictegravir (1 or 5 mg/mL), cabotegravir
(1 mg/mL), and doravirine (2 mg/mL) were prepared in DMSO.
Rilpivirine powder was dissolved in a mixture of DMSO:MeOH 1:1 to
obtain the final concentration of 0.5 mg/mL. These stock solutions
were stored at −20C for bictegravir, cabotegravir, and doravirine.
The stock solution of rilpivirine was stored at +4C, as currently done
for the routine monitoring of rilpivirine plasma concentrations in the
framework of our TDM service.18
One working solution (WS) at 100 μg/mL for bictegravir,
cabotegravir, and doravirine and 20 μg/mL for rilpivirine was prepared
in a mixture of H2O:DMSO (3:1) for calibration standards. Another WS
for validation standards was independently prepared in the same sol-
vent, at the following concentrations: 90 μg/mL for all analytes except
for rilpivirine (18 μg/mL). Spiking solutions for calibration and validation
samples were prepared at the appropriate concentrations by sequen-
tially diluting the WSs in a mixture of H2O:DMSO (3:1).
Stock solutions of each IS were prepared at 1 mg/mL in DMSO
(isotopically labelled bictegravir and cabotegravir) or MeOH (isotopi-
cally labelled rilpivirine and doravirine) and stored at −20C. An IS-WS
was prepared at 250 ng/mL for all analytes, except for rilpivirine
(50 ng/mL) by mixing the required volumes of the four IS stock solu-
tions with a mixture of MeOH:ACN 1:1.
All solutions were stored at −20C.
2.3 | Calibration and validation standards
preparation
Spiked plasma was obtained by diluting tenfold the spiking solutions
(100 μL) with blank plasma (900 μL). The total added volume was
≤10% of the biological sample volume to follow the recommendations
for bioanalytical method validation.25,26 Nine concentration levels
(k) of calibration samples were prepared each validation day (n = 3) at
the following concentrations: 10 000, 5000, 2500, 1000, 500, 250,
125, 50, and 25 ng/mL, except for rilpivirine with fivefold lower con-
centrations (ie, 2000, 1000, 500, 200, 100, 50, 25, 10, and 5 ng/mL),
with respect to the values commonly observed in clinical
practice.14,27,28 Eight validation standards were prepared at the fol-
lowing concentrations: 9000, 4500, 1500, 600, 300, 150, 60, and
30 ng/mL, except for rilpivirine, having fivefold lower values. For each
analyte, accurate determination of lower limits of quantifications
(LLOQs) relied on the use of one validation sample at the estimated
LLOQ and one at twofold to threefold LLOQ.
2.4 | Plasma pre-treatment procedure
Protein precipitation was operated by adding a 300-μL volume of the
IS-WS to 100 μL of calibration, validation, or patient plasma samples.
The mixture was vortexed and centrifuged at 18 620g (14 000 rpm) at
+4C for 10 minutes with a benchtop centrifuge (Benchtop Mikro 220R
centrifuge, Hettich, Bäch, Switzerland). Three hundred microliters of
the supernatant were directly transferred into an HPLC vial with insert.
2.5 | UHPLC-MS/MS instrumentation
UHPLC-MS/MS analyses were conducted using an Ultimate 3000
Rapid Separation (RS) LC system (Thermo Fisher Scientific, San Jose,
CA, USA) composed of an Ultimate 3000 RS column compartment, an
RS autosampler, and an RS binary pump. Chromatographic separation
was carried out with a Xselect HSS T3 analytical column from Waters
(Milford, MA, USA) with 3.5-μm particle size and dimensions of 2.1 ×
75 mm. The UHPLC system was coupled with a TSQ Quantis triple
quadrupole mass spectrometer from Thermo Fisher Scientific,
equipped with an OptaMax NG ion source used in electrospray ioniza-
tion (H-ESI) mode. Data acquisition, treatment, and instrument control
were performed using the XCalibur software version 4.1.31.9 and
Chromeleon version DCMS link (ThermoFisher Scientific).
2.6 | Analytic conditions
The mobile phases (ie, H2O + 0.1% FA (A) and ACN + 0.1% FA (B))
were delivered at a flow rate of 300 μL/min, following this multistep
gradient: first, linear gradient from 40% to 60% B in 3 minutes, up to
95% B in 0.2 minutes, followed by an isocratic stage at 95% B for
0.8 minutes. Then, solvent B was reduced to 40% (initial conditions) in
0.1 minute, followed by a re-equilibration step up to 5 minutes (total
F IGURE 1 Chemical structures of the analyzed
antiretroviral drugs




analysis time). Samples were stored at +5C in the autosampler, and
the injection volume was 7 μL.
Polarity switching capability enabled ESI positive (spray voltage
3900 V) and negative (spray voltage 3400 V) analysis in the same sam-
ple injection. ESI source parameters were optimized as follows: the
ion transfer tube and vaporizer temperatures at 300C and 150C,
respectively; sheath, auxiliary, and sweep gas flow rates at 45, 25,
and 0 (arbitrary units), respectively. The first (Q1) and third
(Q3) quadrupoles operated with a mass resolution of 1.2 Da (ie, m/z
1.2 full width at half maximum, FWHM). The cycle time was 0.2 sec-
onds. The pressure of the collision gas (argon) in the second quadru-
pole (Q2) was set at 1.5 mTorr.
2.7 | Validation procedure
2.7.1 | Selectivity
The selectivity of the method was evaluated by analyzing blank
human plasma from 10 different donors processed with pure ACN:
MeOH 1:1. Cross-talk interferences were then established by
injecting a high concentration calibration sample processed with pure
ACN:MeOH 1:1 (no ISs) and a blank plasma processed with the IS-
WS. Finally, the injection of blank solvent (ACN:MeOH 1:1) or blank
plasma extract immediately after a high calibration sample processed
with IS-WS allowed the assessment of carryover effect.
In addition, since the INSTIs bictegravir and cabotegravir are
metabolized by UDP-glucuronosyltransferase (UGT) to glucurono-
conjugated metabolites, the separations between drug and their
metabolites were investigated. This was particularly important to
ascertain that these INSTIs and their respective glucuronides do
not coelute that would give spuriously high drug levels because of
the in-source dissociation of glucuronide to parent compound dur-
ing the ionization step, such as previously reported for
raltegravir.29,30 Cabotegravir glucuronide was provided by Alsachim,
whereas bictegravir glucuronide was not available at the time of
the current development. MS/MS transition of cabotegravir glucu-
ronide was assessed by direct infusion into the MS detector.
Bictegravir glucuronide MS/MS transition was empirically reckoned,
considering that bictegravir was the main fragment obtained from
bictegravir glucuronide. The selectivity of the method regarding
glucuronides was evaluating by injecting a plasma sample con-
taining cabotegravir and cabotegravir glucuronide processed with
blank MeOH:ACN (1:1) and a plasma sample from an HIV-infected
patient receiving bictegravir.
2.7.2 | Matrix effect, extraction recovery, and
process efficiency
Qualitative evaluation of matrix effect
The method proposed by Bonfiglio et al31 allowed the evaluation of the
potential impact of endogenous compounds on ionization process. A
solution of analytes in MeOH (1100 ng/mL for bictegravir, cabotegravir,
and doravirine and 200 ng/mL for rilpivirine) and ISs (200 ng/mL for all
IS except for [13C6]-rilpivirine at 50 ng/mL) was continuously infused
postcolumn, while seven different blank plasma extracts processed with
pure ACN:MeOH 1:1 were injected into the UHPLC-MS/MS system.
Each MS/MS transition was visually examined to check for any alter-
ation (suppression or enhancement) at the analytes' retention times.
Quantitative assessment of matrix effect, extraction recovery, and
process efficiency
Matrix effects (MEs), extraction recoveries (ERs), and process efficien-
cies (PEs) were quantitatively evaluated following Matuszeswski's
approach.32 Low (60 ng/mL for bictegravir, cabotegravir, and doravirine
and 12 ng/mL for rilpivirine), medium (600 ng/mL for bictegravir, cab-
otegravir, and doravirine and 120 ng/mL for rilpivirine), and high (6000
ng/mL for bictegravir, cabotegravir, and doravirine and 1200 ng/mL for
rilpivirine) concentrations were considered. Three sets of samples at the
three concentration levels were prepared as follows: (A) three neat solu-
tions (H2O) with analytes and ISs; (B) seven postextraction spiked blank
plasma in duplicate; (C) seven pre-extraction spiked blank plasma in
duplicate. IS normalization was considered by using ratio of analyte
peak areas to the corresponding IS peak area to calculate the following
parameters: IS-normalized matrix effects (IS-nMEs) as B/A (in %), IS-
normalized extraction recoveries (IS-nERs) as C/B (in %), and IS-
normalized process efficiencies (IS-nPEs) as C/A (in %).
Relative standard deviation (RSD) of slopes from linear regres-
sions estimated at L, M, and H concentrations were also calculated.
An LC-MS/MS method is considered devoid of significant ME if RSD
value is <4%.
2.7.3 | Trueness, precision, accuracy profiles, limits
of quantification, and linearity
Trueness and precision of the method were assessed over three differ-
ent days. Several regression models were fitted to adequately describe
the response concentration profile. The selection of the best calibration
model was based on the estimations of trueness and precision, the
narrowest β-expectation tolerance interval, and the lowest LLOQ.33
Concentrations of the validation standards were back-calculated
with the daily calibration curve. The trueness (systematic error) was
defined as the percentage of deviation between the calculated concen-
trations of validation standards and the nominal value. The precision
(random error) was estimated by two components: the repeatability
(intraday variances) and intermediate precision (intraday and interday
variances).34-36 Precision parameters were reported as RSD at each
concentration level.33 The total error encompassed both systematic
and random errors and was evaluated using accuracy profiles. β-
expectation tolerance intervals represent the concentration range
where β% of future results is expected to lie.37-39 Using data obtained
during the validation phase, this approach allows to confidently predict
the future results that will be obtained during the routine use of the
method. Based on the absolute accuracy profiles, LLOQ was graphically
interpolated as the lowest concentration for which the β-expectation
tolerance interval crosses the acceptance limits (±30%).25,26,40




Finally, the capacity of the method to give quantitative results
proportional to nominal concentrations was evaluated by ordinary
least square regression on the plot representing back-calculated con-
centrations vs nominal concentrations. This defines the linearity of
trueness and was assessed each day of validation.
2.7.4 | Measurement uncertainty
An analytical result should also be reported with respect to its mea-
surement uncertainty (MU). MU was evaluated by the type A estima-
tion method, based on experimental measurements. Feinberg et al
demonstrated that the β-expectation tolerance interval is directly
related to the MU.41 The accuracy profile validation methodology
enables the estimation of MU without any additional experiments.42
MU can be derived from the data collected during the validation
phase, by fixing the β value at 0.95. Continuous models were devel-
oped in order to obtain values of MU as a function of the concentra-
tion of the analytes. Several models were tested to identify the one
that fitted the data best, by visual inspection of the uncertainty pro-
files. Ordinary least squares regression was used to estimate the coef-
ficients of the uncertainty function. This methodology allows easy
calculation of the MU at any concentration within the validation
domain. All calculations were performed using Excel.
2.7.5 | Stability studies
Stability studies included bench- and long-term stabilities. The stabil-
ity of plasma at room temperature (RT) and in the fridge (+4C) up to
48 hours was evaluated. In addition, stability after three freeze/thaw
cycles was assessed by thawing frozen samples at RT for 1 hour and
refreezing them during 1 hour, three times in a row. Furthermore,
plasma samples were submitted to thermal viro-inactivation process
(60 min at +60C in a water bath) since this procedure has been
shown to efficiently inactivate HIV particles present in the sam-
ples.43,44 Finally, medium stability was evaluated with plasma samples
frozen at −20C and −80C during 6 weeks. Analyses were performed
in triplicate. The mean of the concentrations obtained after each sta-
bility study were compared with the mean concentration of samples
prepared at time 0.
2.8 | Patients samples
Blood samples were collected from PLWH at the request of physicians
during their usual follow-up visits. In the frame of the hospital routine
TDM program for ARV drugs, TDM was performed rather liberally,
being particularly recommended in case of suspicion of altered phar-
macokinetics (eg, DDIs or impaired hepatic/renal functions) or to eval-
uate short-term adherence to oral ARV drugs. Blood samples were
collected in EDTA-Monovettes. The preanalytical sample preparation
was performed in our laboratory by centrifuging the Monovettes,
transferring plasma into propylene tubes in class II biohazard hoods
using standard biosafety precautions (gloves and others) and storing
samples at −20C until batch analyses.
3 | RESULTS
3.1 | Analytical method development
The optimization of the LC-MS/MS assay aimed at improving sensitiv-
ity while minimizing runtime. First, standard solutions of each analyte
at 5 μg/mL in MeOH were directly infused into the MS detector in
order to select optimal MS/MS, as reported in Table 1. LC-MS/MS
transitions for bictegravir and rilpivirine differed from reported values.
TABLE 1 MS/MS parameters and typical retention times of the four ARV drugs and their respective stable isotope–labelled ISs
Compound ESI polarity (+/−) Precursor Ion (m/z) Product Ion (m/z) Collision Energy (V) Typical Retention Time, min
Bictegravir − 448.4 286.2 25 2.16
− 301.0 25
[13C,2H2,
15N]-Bictegravir − 452.2 203.0 35 2.13
− 287.1 25
Cabotegravir − 404.2 305.1 26 1.74
− 374.1 22
[13C,2H5]-Cabotegravir − 410.2 311.1 27 1.72
− 380.0 23
Doravirine + 426.1 111.9 24 2.35
+ 315.1 18
[13C6]-Doravirine + 432.5 320.8 10 2.35
+ 416.4 11
Rilpivirine − 365.1 142.1 30 1.41
[13C6]-Rilpivirine − 371.2 148.1 31 1.41
− 329.3 25
Abbreviations: ARV, antiretroviral; IS, internal standard; MS/MS, tandem mass spectrometry.




In the only published bioassays for bictegravir, mass spectrometer
operated in ESI positive mode, while in our study, bictegravir sensitiv-
ity was higher in the negative mode.21,22 In most of published
methods for the quantification of rilpivirine, MS/MS transition was
367/195 in the positive mode.18,20,45 However, the infusion of a
rilpivirine solution into the MS detector revealed a higher sensitivity
in the negative mode. This was certainly due to the fact that one main
fragment with high intensity was observed in ESI− whereas multiple
fragments with shared intensities were present after fragmentation in
ESI+. Nevertheless, transition 367/195 in the positive mode was tested
during method development, and the lower sensitivity was confirmed.
Therefore, transition 365/142 in the negative mode was finally retained
for the quantification of rilpivirine in this bioanalytical assay. Since no
LC-MS/MS method had been yet reported for the determination of
F IGURE 2 Ultrahigh-performance liquid chromatography coupled to tandem mass spectrometry (UHPLC-MS/MS) separation of a calibration
sample containing the four antiretroviral drugs, at the concentration of 10 000 ng/mL for all the analytes except for rilpivirine (2000 ng/mL).
Calibration sample was prepared as described in Section 2 [Colour figure can be viewed at wileyonlinelibrary.com]




cabotegravir and doravirine, no comparison between transitions could
be made.
Concerning the chromatographic part of the method, analytical
efforts have been made to achieve satisfactory separation and
peak shape, in order to accurately quantify each analyte. For that
purpose, conventional mobile (ie, H2O + 0.1% FA and ACN + 0.1%
FA) and stationary (Xselect HSS T3 column) phases were shown to
be suitable. Mobile-phase gradient program was optimized to ade-
quately separate each analyte in a minimal runtime. Sample prepa-
ration was limited to a convenient and fast protein precipitation,
which was considered sufficient to accurately quantify the range of
concentrations commonly observed in clinical practice. Sensitivity
was compared between different protein precipitation solvents, and
a mixture of MeOH:ACN 1:1 was selected instead of MeOH or
TABLE 2 Internal standard–normalized matrix effect (IS-nME), extraction recovery (IS-nER), and process efficiency (IS-nPE) in human plasma
Compound QC Levela
IS-nME IS-nER IS-nPE
% (RSD) % (RSD) % (RSD)
Bictegravir/[13C,2H2,
15N]-Bictegravir Low 0 (6) −6 (6) −6 (7)
Middle 3 (3) −5 (3) −2 (2)
High −5 (3) −8 (4) −12 (3)
Cabotegravir/[13C, 2H5]-Cabotegravir Low 5 (4) −6 (6) −1 (5)
Middle −1 (3) −6 (4) −6 (3)
High −6 (3) −7 (3) −12 (3)
Doravirine/[13C6]-Doravirine Low 3 (5) −11 (5) −8 (3)
Middle 4 (3) −8 (3) −5 (2)
High −4 (2) −10 (3) −13 (3)
Rilpivirine/[13C6]-Rilpivirine Low 12 (4) −15 (10) −5 (8)
Middle 9 (5) −4 (8) 5 (3)
High −6 (3) −11 (6) −16 (4)
Abbreviation: RSD, relative standard deviation.
aLow concentrations are defined as 60 ng/mL (12 ng/mL for rilpivirine), middle concentrations are defined as 600 ng/mL (120 ng/mL for rilpivirine), and
high concentrations are defined as 6000 ng/mL (1200 ng/mL for rilpivirine).
F IGURE 3 Qualitative assessment of matrix effect. Overlaid ultrahigh-performance liquid chromatography coupled to tandem mass
spectrometry (UHPLC-MS/MS) profiles obtained from seven blank plasma extracts during postcolumn infusion of a solution containing the four
analytes, as described in Section 2.7.2. Chromatographic peaks obtained during experiments were superimposed for interpretation [Colour figure
can be viewed at wileyonlinelibrary.com]




ACN. Different injection volumes of pretreated samples ranging
from 3 to 10 μL were tested, and a volume of 7 μL was finally
chosen as the best compromise between suitable sensitivity and
satisfactory peak shape. As shown in Figure 2, an adequate separa-
tion of the four analytes was achieved in less than 3 minutes, with
satisfactory peak shapes.
The MS part of the analytical assay was optimized (as reported
in Section 2.6) by choosing the appropriate ESI source parameters
to improve sensitivity while minimizing background noise.
Finally, IS concentrations were selected to obtain satisfying IS-
normalized response functions, by avoiding variability due to
low IS concentrations and by circumventing a significant
contribution of IS signal to analyte signal in case of excessive IS
concentrations.
3.2 | Validation of the method
3.2.1 | Selectivity and carryover
The good selectivity of the chromatographic method was demon-
strated with the absence of interference at the retention times of the
four analytes when analyzing human blank plasma from 10 different
sources.
The injections of a blank plasma processed with IS-WS or the
highest calibration standard processed with MeOH:ACN (1:1) did not
reveal any significant signal on the analytes or IS transitions, respec-
tively, demonstrating the absence of cross talks.
The additional experiments regarding the selectivity with the
glucurono-conjugated metabolites demonstrated that retention times
TABLE 3 Trueness, repeatability, and intermediate precision in human plasma over the validated range
Compound Concentration, ng/mL Trueness, %
Precision
Relative Uncertainty, %Repeatability, % Intermediate Precision, %
Bictegravir 30 106.2 9.6 9.6 27.2
60 107.5 6.2 6.2 17.6
150 103.1 7.8 7.8 22.0
300 97.8 3.4 3.8 11.3
600 96.6 6.0 6.0 15.2
1500 97.0 4.0 4.1 11.6
4500 96.5 4.3 4.3 12.1
9000 101.6 6.5 6.5 18.4
Cabotegravir 30 94.7 11.0 11.2 41.4
60 101.3 6.7 11.1 41.4
150 97.7 5.6 8.5 29.8
300 101.5 4.0 6.6 24.1
600 99.8 2.6 3.0 9.0
1500 103.9 4.3 4.3 12.2
4500 97.1 3.5 3.5 10.0
9000 97.7 3.5 3.5 9.9
Doravirine 30 104.0 4.0 4.0 11.2
60 102.2 2.8 3.7 12.3
150 100.8 3.4 3.4 9.5
300 100.7 3.2 3.5 10.3
600 100.2 3.0 4.3 14.8
1500 102.2 3.6 4.4 14.0
4500 97.9 3.3 3.3 9.3
9000 99.4 3.1 3.3 9.6
Rilpivirine 12 100.9 7.6 7.6 21.4
30 107.5 5.4 6.2 18.8
60 100.7 6.9 6.9 19.4
120 101.5 4.3 4.3 12.1
300 106.3 4.5 4.8 14.0
900 101.1 3.7 3.9 11.3
1800 100.1 3.7 3.9 11.1




for cabotegravir glucuronide and bictegravir glucuronide were 0.83
and 0.89 minutes, respectively. In consequence, they were adequately
separated from their respective parent drug, cabotegravir and
bictegravir, eluting at 1.74 and 2.16 minutes, respectively.
Carryover was considered satisfactory since the chromatogram of
blank matrix samples or MeOH directly injected after the highest cali-
bration standard was devoid of analytes' and IS traces.
3.2.2 | ME, ER, and PE
As shown in Figure 3, no major interferences (ie, ion suppression or
enhancement) were observed at analytes' retention times. This result
supports the suitability of the chromatographic method, preventing an
impact of endogenous plasma components on the ionization process
of the four analytes and ISs.
Quantitative results of the assessment of IS-nME, IS-nER, and
is-nPE are summarized in Table 2. The IS-nME of the analytes was
considered satisfactory and varied from −6% to 12%, while RSD
values were lower than 6%. Regarding IS-nER and IS-nPE, accept-
able results were observed with values ranging from −15% to 4%
and −16% to 5%, respectively, with RSD lower than 10%. Overall,
matrix-matched calibration along with the use of isotopically
labelled IS was found to adequately limit MEs issues.
The lack of significant ME was corroborated by the standard line
slopes approach, with RSD values of 2.0%, 1.7%, 2.3%, and 1.8% for
bictegravir, cabotegravir, doravirine, and rilpivirine, respectively.
3.2.3 | Trueness, precision, and accuracy profile
Analyte/IS peak area ratios were plotted vs analyte concentrations to
obtain response functions. The quadratic log-log regression model
provided the best description of the response-concentration profile in
terms of determination coefficient and back-calculated calibration
samples (±15% and ±20% at expected LLOQ) and was finally retained
for each compound. For each series, plasma levels of the validation
standards were then calculated using the calibration curves. The vali-
dated calibration ranges varied from 25 to 10 000 ng/mL for
bictegravir, cabotegravir, and doravirine and from 10 to 2000 ng/mL
for rilpivirine. Trueness (94.7% to 107.5%), repeatability (2.6% to
11.0%), and intermediate precision (3.0% to 11.2%) were appropriate
for quantifying plasma levels of the four ARV drugs of interest
(Table 3).
A β value of 80% was chosen for the establishment of β-
expectation tolerance intervals, representing the fraction of future
results that would be expected to fall within the obtained tolerance
intervals during routine application of the method.46 As demonstrated
in Figure 4, accuracy profiles obtained for each compound lie within
the acceptance limits of ±30% for biological samples.26
Since the β-expectation tolerance interval of bictegravir, cab-
otegravir, and doravirine does not cross the acceptance limits of
±30%, the LLOQ was defined as the concentration of the lowest
validation sample (ie, 30 ng/mL). Considering an accuracy of ±30%
(total error), the lowest concentration measurable in human plasma
(LLOQ) was 10 ng/mL for rilpivirine.
Linearity was considered satisfactory since slopes and intercepts
ranged from 0.96 to 1.03 and −75.4 to 40.2, respectively. In addition,
determination coefficient (R2) were all higher than .99.
3.2.4 | Measurement uncertainty
The absolute uncertainty vs concentration profiles were best
described by polynomial (bictegravir, cabotegravir, and doravirine) and
power regression models (rilpivirine).
F IGURE 4 Accuracy profiles over the validated domain in human
plasma of the five comedications and the two metabolites. Trueness
(red solid line), upper and lower β-expectation tolerance intervals (β =
80%) (black solid lines) and acceptance limits (λ = ±30%, green dotted
lines) are shown [Colour figure can be viewed at wileyonlinelibrary.
com]




The relative uncertainty of each compound at each validation
levels is shown in Table 3. With a confidence level of 95%, the
unknown true value located at maximum ±27.2%, ±41.4%, ±14.8%,
and ±21.4% around the measured result for bictegravir, cabotegravir,
doravirine, and rilpivirine, respectively. Table 3 also demonstrates that
the relative uncertainty is higher at the lowest concentrations of the
validation domain.
3.2.5 | Stability studies
Stability of analytes in plasma is reported in Table 4. Results demon-
strated that analytes did not significantly degrade after storage of
plasma samples at room temperature and +4C for up to 48 hours. In
addition, no significant alteration of plasma concentrations was
observed after three consecutive freeze-thaw cycles (variation <
±15%). The thermal viro-inactivation process had no significant influ-
ence on analytes concentrations, with variations comprised between
−6.5% and 10.6%. Finally, medium-term stability studies showed no
significant influence of degradation after 6 weeks of freezing at
−20C and −80C.
3.3 | Clinical applications
The proposed LC-MS/MS assay has been applied to patient's samples
obtained for clinical purposes, within the framework of our TDM ser-
vice. A typical chromatographic profile of a plasma from an HIV-
infected patient receiving bictegravir 50 mg once daily is shown in
Figure 5A. Plasma sample was collected 17.25 hours after the last






























Bictegravir 60 −8.0 −10.4 −4.8 −9.3 −10.5 −6.3 −8.2 −11
600 6.7 11.4 3.8 −4.3 −0.9 −2.6 8.3 11.9
6000 5.1 9.6 4.9 0.7 −5.9 10.4 10.0 1.0
Cabotegravir 60 −5.4 −9.5 −10.3 −5.9 −12.9 −6.4 3.1 12.9
600 2.8 5.0 10.1 5.0 8.2 9.8 14.4 13.6
6000 6.2 6.8 6.3 7.3 6.4 7.1 12.5 13.4
Doravirine 60 −7.0 −6.2 −2.6 −6.4 −7.6 3.2 −8.9 −5.0
600 −2.1 0.0 1.9 3.7 2.2 7.1 8.0 9.6
6000 −3.0 3.9 4.0 0.0 0.5 2.7 −0.7 1.9
Rilpivirine 12 8.9 14.5 12.9 11.9 −2.1 10.5 −11.4 −5.3
120 11.3 9.4 8.8 10.7 2.9 7.2 10.8 11.9
1200 2.4 8.8 7.9 6.4 −0.3 1.9 5.4 2.1
Note. Data are reported as deviations (%) from concentration measured at t0.
a60 min at 60C in a water bath.
F IGURE 5 Chromatographic profile of a plasma from one HIV-infected individual receiving bictegravir 50 mg once daily (A) and from another
patient receiving doravirine 100 mg once daily (B) [Colour figure can be viewed at wileyonlinelibrary.com]




drug intake, and plasma concentration of bictegravir was 3351 ±
340 ng/mL.
At present, 32 plasma samples from PLWH receiving
bictegravir have been collected in our TDM service. The interpreta-
tion of these plasma concentrations was made possible thanks to
the availability of a population pharmacokinetic model summarized
in the European Public Assessment Report.47,48 Using the Tucuxi
software49,50 developed by our service, the pharmacokinetic profile
of bictegravir at steady state was simulated over the dosing inter-
val, exploiting the reported intraindividual and interindividual vari-
abilities. The 32 plasma concentrations determined using the
proposed LC-MS/MS assay were compared with the simulated
population pharmacokinetic profile to ascertain the expectedness
of the result. As shown in Figure 6, 59% (n = 19) and 94% (n =
30) of the measured bictegravir plasma concentrations lied into the
50% and 95% prediction interval, respectively. This result demon-
strates the ability of our LC-MS/MS methodology to quantify
bictegravir and to replicate the manufacturer's findings regarding
the rather large variability of plasma concentrations commonly
observed in clinical practice.
In addition, the chromatographic profile of an HIV-infected indi-
vidual receiving doravirine 100 mg once daily is shown in
Figure 5B. Doravirine plasma concentration measured in this patient
was 1139 ± 124 ng/mL, 15 hours after the last drug intake.
Finally, the combination of LAI cabotegravir/rilpivirine, injected
monthly, has been demonstrated as effective as the daily, oral, three-
drug regimen in maintaining HIV virus suppression throughout a
48-week period.9,10,51 The LAI cabotegravir/rilpivirine formulation
(Cabenuva) is therefore currently being reviewed by the Food and
Drug Administration. Once used in the clinical setting, it is anticipated
that physicians will be asking for cabotegravir and rilpivirine levels
measurement in patients on LAI cabotegravir/rilpivirine, for the moni-
toring of their plasma drug exposure in special clinical situations such
as the initiation of treatments for inaugural diseases with definite risk
of DDIs (tuberculosis, epilepsy, HCV infection, or cancer). Finally,
although no clear correlation has been established between cab-
otegravir and rilpivirine plasma concentrations and the emergence of
resistance during the phase 2 study LATTE-2,14 the management of
failure of ARV drug remains crucial.52 This bioanalytical assay offers
clinicians the possibility to closely monitor the plasma levels of cab-
otegravir and rilpivirine in the special instances where LAI-ARV drug
needs to be stopped and switched to oral intake of ARV drugs.
4 | CONCLUSION
A sensitive and selective LC-MS/MS assay was developed and vali-
dated, enabling the simultaneous quantification in human plasma of
four newly approved ARV agents, or ARV drugs at the latest phase of
their development. Validation performances met international recom-
mendations for bioanalytical assay and were achieved over a large val-
idation domain that covers the plasma concentrations commonly
observed in clinical practice. The method could be easily implemented
for both clinical and research purposes. Our assay thus provides
important information on the plasma levels of these latest generation
ARV drugs in PLWH patients and constitutes a useful TDM tool for
ascertaining that they are always exposed to suitable systemic drug
exposure in the various clinical situations that do occur in the real-life
conditions.
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